Series
Radiotherapy
Status
Published
Date
Number of report
026
Stereotactic body radiation therapy
Ask the expert
The report presents a summary of reimbursement situation for stereotactic body radiation therapy (SBRT) in European countries.
Sample pages are provided for an older version of the report. Before delivery to the client, the report is updated to the current state (e.g., 2022 coding, tariffs, and policy considerations).
The analysis covers the application of SBRT in primary liver cancer and lung cancer.
The analysis is provided for the session and out-patient treatment, including both preparation and delivery of SBRT. The only reimbursement within public / statutory health insurance systems is considered.
The report includes essential information about reimbursement, including:
- Brief country-specific overview of reimbursement system
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions on indications or scenarios for the use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- Austria
- Belgium
- Denmark
- England (UK)
- Finland
- France
- Germany
- Italy
- The Netherlands
- Norway
- Sweden
- Switzerland
It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.
Manufacturers of equipment for stereotactic body radiation therapy include:
- Accuray (CyberKnife)
- Brainlab (Novalis)
- Elekta (Versa HD)
- Varian Medical Systems (TrueBeam, Trilogy, Clinac iX)
Table of content
1. Introduction and summary
2. Executive summary table
3. Contents
4. Abbreviations
5. Methodology
6. Reimbursement analysis in Austria
6.1. Overview of the reimbursement system
6.2. Reimbursement for stereotactic body radiation therapy
6.2.1. Procedure coding
6.2.2. Diagnosis coding
6.2.3. Payment mechanism and reimbursement tariffs in outpatient settings
6.2.4. Payment mechanism and reimbursement tariffs in hospital admission
6.2.5. Health technology assessments by LBI-HTA
7. Reimbursement analysis in Belgium
7.1. Overview of the reimbursement system
7.2. Reimbursement for stereotactic body radiation therapy
7.2.1. Procedure coding
7.2.2. Payment mechanism and reimbursement tariffs
7.2.3. Policy considerations by the INAMI/RIZIV
7.2.3.1. Health technology assessments by KCE
8. Reimbursement analysis in Denmark
8.1. Overview of the reimbursement system
8.2. Reimbursement for stereotactic body radiation therapy
8.2.1. Procedure coding
8.2.2. Diagnosis coding
8.2.3. Payment mechanism and reimbursement tariffs
8.2.4. Policy considerations
9. Reimbursement analysis in England
9.1. Overview of the reimbursement system
9.2. Reimbursement for stereotactic body radiation therapy
9.2.1. Procedure coding
9.2.2. Payment mechanism and reimbursement tariffs
9.2.3. Policy considerations
9.2.3.1. Specifics of commissioning of the procedure
9.2.3.2. Health technology assessments by NICE
10. Reimbursement analysis in Finland
10.1. Overview of the reimbursement system
10.2. Reimbursement for stereotactic body radiation therapy
10.2.1. Procedure coding
10.2.2. Diagnosis coding
10.2.3. Payment mechanism and reimbursement tariffs
10.2.4. Policy considerations
11. Reimbursement analysis in France
11.1. Overview of the reimbursement system
11.2. Reimbursement for stereotactic body radiation therapy
11.2.1. Procedure coding
11.2.2. Diagnosis coding
11.2.3. Payment mechanism and reimbursement tariffs
11.2.4. Policy considerations by HAS
12. Reimbursement analysis in Germany
12.1. Overview of the reimbursement system
12.2. Reimbursement for stereotactic body radiation therapy
12.2.1. Procedure coding
12.2.2. Diagnosis coding
12.2.3. Payment mechanism and reimbursement tariffs
12.2.4. Policy considerations by G-BA
12.2.5. Selective contracts
13. Reimbursement analysis in Italy
13.1. Overview of the reimbursement system
13.2. Reimbursement for stereotactic body radiation therapy
13.2.1. Procedure coding at national level
13.2.2. Procedure coding at regional level (Emilia-Romagna, Lombardy, Veneto regions)
13.2.3. Diagnosis coding
13.2.4. Payment mechanism and reimbursement tariffs at national level
13.2.5. Payment mechanism and reimbursement tariffs at regional level
13.2.6. Policy considerations
14. Reimbursement analysis in the Netherlands
14.1. Overview of the reimbursement system
14.2. Reimbursement for stereotactic body radiation therapy
14.2.1. Procedure coding
14.2.2. Diagnosis coding
14.2.3. Payment mechanism and reimbursement tariffs
14.2.4. Policy considerations by Dutch Healthcare Institute (ZIN)
15. Reimbursement analysis in Norway
15.1. Overview of the reimbursement system
15.2. Reimbursement for stereotactic body radiation therapy
15.2.1. Procedure coding
15.2.2. Diagnosis coding
15.2.3. Payment mechanism and reimbursement tariffs
15.2.4. Policy considerations
16. Reimbursement analysis in Sweden
16.1. Overview of the reimbursement system
16.2. Reimbursement for stereotactic body radiation therapy
16.2.1. Procedure coding
16.2.2. Diagnosis coding
16.2.3. Payment mechanism and reimbursement tariffs
16.2.4. Policy considerations
17. Reimbursement analysis in Switzerland
17.1. Overview of the reimbursement system
17.2. Reimbursement for stereotactic body radiation therapy
17.2.1. Procedure coding
17.2.2. Payment mechanism and reimbursement tariffs
17.2.3. Policy considerations
18. Summary of procedure codes
19. Summary of reimbursement codes and tariffs
20. Disclaimer
16
Mar 2023
In January-February 2023, Health Technology Wales published sixteen Medtech-related Topic Exploration Reports (TER), including stereotactic radiosurgery, percutaneous implantation of pulmonary artery pressure sensors, ambulatory patch ECG devices, and others; however, Health Technology Wales will not proceed with full appraisals on these topics. No Guidance was released for Medtech in January-February 2023.
Read more24
Feb 2023
In February 2023, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclatures for private payers in England, published Bulletins 188 and 084 with changes to be implemented no later than March 23, 2023. Five new procedure codes (concerning interventional radiology, robotic surgery, and radiotherapy) and one new diagnostic code were introduced.
Read more15
Feb 2023
In February 2023, it was announced that the Basque Office for Health Technology Assessment (OSTEBA) initiated several HTAs, including evaluations in the e-health, radiology, nephrology and urology, cardiovascular, IVD, obstetrics and gynecology, diagnostic imaging, radiotherapy, neurovascular, ENT, interventional radiology, surgical procedures, and some other fields.
Read more12
Jan 2023
In December 2022, the National Institute for Health and Care Excellence (NICE) published one new Medical Technologies Guidance (Memokath 051 Ureter stent for ureteric obstruction) and one MedTech Innovation Briefing (PromarkerD). Also, two new clinical guidelines were published, and one was updated.
Read more08
Sep 2022
The French National Authority for Health released new recommendations about add-on reimbursement of medical devices from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies in August 2022. One recommendation was published in relation to the registration for devices in the List of reimbursable products and services (LPPR List). The opinion concerns men’s health area.
Read more